Dublin medtech OncoMark raises €2.1m in funding

Firm ends to prevent ineffective treatment for early stage breast cancer

Dawn Walsh, Kernel Capital; Des O’Leary, chief executive, OncoMark; Professor William Gallagher, director, UCD Conway Institute and co-founder, OncoMark; Deirdre Glenn, manager, Lifesciences Sector, Enterprise Ireland, and Kevin Healy, senior manager, Corporate Banking Ireland, Bank of Ireland

Company: Oncomark

Done deal:€2.1m investment

The clincher:“OncoMark aims to prevent early stage breast cancer patients’ exposure to ineffective treatment and needless toxicity” - Orla Rimmington, partner, Kernel Capital

OncoMark, the Dublin medtech developing early-stage diagnostic technology for breast cancer patients, has raised funding of €2.1 million.

Investors include Bank of Ireland Kernel Capital Venture Funds, the Irrus Investments syndicate and Galway HBAN MedTech syndicate. The round follows €2.7 million in investment secured by ...